250 related articles for article (PubMed ID: 28602103)
1. Advances in small molecule therapy for treating metastatic thyroid cancer.
Krajewska J; Gawlik T; Jarzab B
Expert Opin Pharmacother; 2017 Aug; 18(11):1049-1060. PubMed ID: 28602103
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
3. Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Tsoli M; Alexandraki KI; Spei ME; Kaltsas GA; Daskalakis K
Horm Metab Res; 2020 Jan; 52(1):25-31. PubMed ID: 31665790
[TBL] [Abstract][Full Text] [Related]
4. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
6. Update on multikinase inhibitor therapy for differentiated thyroid cancer.
Agrawal VR; Jodon G; Mushtaq R; Bowles DW
Drugs Today (Barc); 2018 Sep; 54(9):535-545. PubMed ID: 30303494
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of lenvatinib in treating thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the treatment of thyroid cancer: an updated review.
Krajewska J; Handkiewicz-Junak D; Jarzab B
Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317
[TBL] [Abstract][Full Text] [Related]
11. Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.
Kaae AC; Kreissl MC; Krüger M; Infanger M; Grimm D; Wehland M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830100
[TBL] [Abstract][Full Text] [Related]
12. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
Vaccher E; Schioppa O; Martellotta F; Fornasier G; Giacomin E; Re FL; Baldo P; Corona G; Gobitti C
Recent Pat Anticancer Drug Discov; 2019; 14(3):226-241. PubMed ID: 31362663
[TBL] [Abstract][Full Text] [Related]
13. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
14. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
16. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Wang E; Karedan T; Perez CA
Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026
[TBL] [Abstract][Full Text] [Related]
17. Multikinase Inhibitor Treatment in Thyroid Cancer.
Ancker OV; Krüger M; Wehland M; Infanger M; Grimm D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861373
[TBL] [Abstract][Full Text] [Related]
18. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
20. [Lenvatinib in radioiodine refractory thyroid carcinomas].
de la Fouchardiere C
Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
